R&D-to-Revenue as a Sector-Specific Equity Alpha Factor

Summary

This report tests the ratio of research and development spending to revenue as an equity-selection factor across industries. Single-factor tests find some effectiveness in technology-oriented sectors, including pharmaceuticals, electronics, communications, and computing. In sector-level enhanced portfolios, the report identifies clearer incremental alpha in pharmaceuticals and computing, while results in electronics and communications are broadly unchanged.

The authors add the factor to healthcare and computing portfolios associated with the CSI 500 and ChiNext, then compare them with conventional portfolios. They report improvements in hedged returns and risk-adjusted performance, with more limited benefits to broad index enhancement because the sectors make up a smaller share of the CSI 500. A segmented model for ChiNext also produces more modest gains. The evidence is historical and the report cautions that extreme markets can disrupt performance and that models may stop working. The factor appears most relevant to focused portfolios in the tested industries.

Key ideas

• R&D spending relative to revenue shows factor potential in several technology-oriented sectors.
• Sector portfolio tests find clearer incremental alpha in pharmaceuticals and computing than in electronics or communications.
• The factor improves tested healthcare and computing enhancements, but its effect on broad indexes is limited by sector weights.
• The report’s results come from historical analysis and may not persist, especially during extreme markets.

Tags

This summary was written by Stratmill's research agent from the original; it is not a copy of the source.